Novavax Financials
| 0A3S Stock | 11.90 3.06 34.62% |
Operating Margin (1.54) | Profit Margin (0.32) | Return On Equity (8.98) |
Novavax | Select Account or Indicator |
Understanding current and past Novavax Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Novavax's financial statements are interrelated, with each one affecting the others. For example, an increase in Novavax's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Novavax's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Novavax. Check Novavax's Beneish M Score to see the likelihood of Novavax's management manipulating its earnings.
Novavax Stock Summary
Novavax competes with Taylor Maritime, Evolution Gaming, Bloomsbury Publishing, Molson Coors, and New Residential. Novavax is entity of United Kingdom. It is traded as Stock on LSE exchange.Specialization | Industrials, Commercial & Professional Services |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| Business Address | 700 Quince Orchard |
| Sector | Commercial Services & Supplies |
| Industry | Industrials |
| Benchmark | Dow Jones Industrial |
| Website | www.novavax.com |
| Phone | 240 268 2000 |
You should never invest in Novavax without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Novavax Stock, because this is throwing your money away. Analyzing the key information contained in Novavax's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Novavax Key Financial Ratios
There are many critical financial ratios that Novavax's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Novavax reports annually and quarterly.| Revenue | 885.19 M | ||||
| Net Income | (657.94 M) | ||||
| Retained Earnings | (4.28 B) |
Novavax Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Other Current Liab | 1.7M | 278.3M | 1.4B | 1.3B | 1.5B | 1.5B | |
| Total Current Liabilities | 25.8M | 579.7M | 2.4B | 2.5B | 2.8B | 3.0B | |
| Other Liab | 12.6M | 3.4M | 175.5M | 185.0M | 212.8M | 223.4M | |
| Net Tangible Assets | (242.8M) | 486.1M | (483.2M) | (760.4M) | (684.4M) | (650.1M) | |
| Retained Earnings | (1.4B) | (1.9B) | (3.6B) | (4.3B) | (3.8B) | (3.7B) | |
| Accounts Payable | 2.9M | 54.3M | 127.1M | 216.5M | 249.0M | 261.4M | |
| Other Assets | 7.5M | 5.4M | 24.3M | 28.5M | 32.7M | 34.4M | |
| Other Current Assets | 7.3M | 103.5M | 56.1M | 86.7M | 99.7M | 58.3M | |
| Other Stockholder Equity | (12.5M) | 7.0M | (1.4M) | (6.4M) | (7.3M) | (7.7M) | |
| Total Current Assets | 97.2M | 1.2B | 2.2B | 1.7B | 2.0B | 1.0B | |
| Common Stock | 324K | 714K | 764K | 868K | 781.2K | 813.2K | |
| Property Plant Equipment | 11.4M | 187.7M | 265.9M | 400.5M | 460.6M | 483.6M |
Novavax Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Income | 12.1M | 10.9M | 12.1M | 14.1M | 16.3M | 13.2M | |
| Selling General Administrative | 34.5M | 34.4M | 34.4M | 145.3M | 167.1M | 175.4M | |
| Total Revenue | 31.2M | 34.3M | 18.7M | 475.6M | 546.9M | 574.3M | |
| Operating Income | (171.7M) | (173.9M) | (120.6M) | (416.7M) | (375.0M) | (356.3M) | |
| Income Before Tax | (183.8M) | (184.7M) | (132.7M) | (418.3M) | (376.4M) | (395.3M) | |
| Net Income Applicable To Common Shares | (132.7M) | (418.3M) | (1.7B) | (657.9M) | (592.1M) | (621.8M) | |
| Net Income | (183.8M) | (184.7M) | (132.7M) | (418.3M) | (376.4M) | (395.3M) | |
| Ebit | (129.6M) | (414.0M) | (1.7B) | (644.7M) | (580.3M) | (609.3M) |
Novavax Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Sale Purchase Of Stock | 64.6M | 102.8M | 98.4M | 1.1B | 1.3B | 1.4B | |
| Change In Cash | 221K | 566.6M | 879.5M | (179.4M) | (206.3M) | (196.0M) | |
| Change In Working Capital | 3.3M | (21.1M) | (24.0M) | 12.0M | 13.8M | 14.5M | |
| Total Cashflows From Investing Activities | 38.5M | (377.8M) | 100.2M | (93.0M) | (83.7M) | (79.5M) | |
| Depreciation | 5.7M | 4.9M | 12.7M | 29.1M | 33.4M | 35.1M | |
| Capital Expenditures | 1.9M | 54.5M | 54.5M | 89.1M | 102.4M | 107.5M | |
| Total Cash From Operating Activities | (136.6M) | (42.5M) | 322.9M | (415.9M) | (478.3M) | (454.4M) | |
| Net Income | (132.7M) | (418.3M) | (1.7B) | (657.9M) | (592.1M) | (621.8M) | |
| Total Cash From Financing Activities | 98.4M | 984.8M | 461.7M | 325.0M | 373.7M | 364.1M | |
| Other Cashflows From Investing Activities | 40.2M | 30.0M | 40.3M | (323.2M) | (290.8M) | (276.3M) | |
| Investments | 30.0M | 22.0M | (157.6M) | 157.6M | 181.3M | 190.4M | |
| Change To Account Receivables | (4.2M) | (422.7M) | (183.4M) | 249.2M | 286.5M | 300.9M | |
| Change To Netincome | 14.4M | 358.8M | 320.4M | 574.1M | 660.2M | 693.2M | |
| Change To Liabilities | (19.8M) | 434.7M | 1.9B | (132.5M) | (152.4M) | (144.8M) |
Novavax Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novavax's current stock value. Our valuation model uses many indicators to compare Novavax value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novavax competition to find correlations between indicators driving Novavax's intrinsic value. More Info.Novavax is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novavax's earnings, one of the primary drivers of an investment's value.Novavax Systematic Risk
Novavax's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Novavax volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Novavax correlated with the market. If Beta is less than 0 Novavax generally moves in the opposite direction as compared to the market. If Novavax Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Novavax is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Novavax is generally in the same direction as the market. If Beta > 1 Novavax moves generally in the same direction as, but more than the movement of the benchmark.
Novavax Other Current Liab Over Time
Novavax December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Novavax help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Novavax. We use our internally-developed statistical techniques to arrive at the intrinsic value of Novavax based on widely used predictive technical indicators. In general, we focus on analyzing Novavax Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Novavax's daily price indicators and compare them against related drivers.
| Downside Deviation | 14.79 | |||
| Information Ratio | 0.0492 | |||
| Maximum Drawdown | 74.87 | |||
| Value At Risk | (22.44) | |||
| Potential Upside | 27.27 |
Additional Tools for Novavax Stock Analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.